Abstract: FR-PO127
Magnesium Levels and Mortality in Critically Ill Patients with AKI
Session Information
- AKI: Diagnosis and Outcomes
October 25, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 102 AKI: Clinical, Outcomes, and Trials
Authors
- Suppadungsuk, Supawadee, Mayo Clinic Minnesota, Rochester, Minnesota, United States
- Thongprayoon, Charat, Mayo Clinic Minnesota, Rochester, Minnesota, United States
- Singh, Waryaam, Mayo Clinic Minnesota, Rochester, Minnesota, United States
- Cheungpasitporn, Wisit, Mayo Clinic Minnesota, Rochester, Minnesota, United States
- Kashani, Kianoush, Mayo Clinic Minnesota, Rochester, Minnesota, United States
Background
Magnesium derangement affects endothelial function and inflammation. It also associated with a declines in renal function and increases the risk of death in chronic kidney disease (CKD) and hemodialysis patients. This study aims to assess the significance of serum magnesium derangements in short—and long-term outcomes among critically ill patients with acute kidney injury.
Methods
This cohort study was conducted among patients with AKI admitted to the intensive care units at Mayo Clinic from January 2007 to December 2017. Serum magnesium levels at AKI onset were categorized into five groups of <1.7, 1.7-1.9, 1.9-2.1, 2.1-2.3, and ≧2.3 mg/dL, with 1.9-2.1 mg/dL as the reference group for outcome comparison. Multivariable logistic regression was used to evaluate the association between serum magnesium levels and mortality.
Results
Among 20,198 critically ill patients with AKI, the mean age was 66±16 years, and 57% were male. The mean serum magnesium at AKI onset was 1.9±0.4 mg/dl. The overall incidence of in-hospital and 1-year mortality were 11.6% and 31%, respectively. In multivariable analysis, hypermagnesemia (>2.3 mg/dl) was associated with increased risk of in-hospital and 1-year mortality with the odds ratio of 1.4 (95% CI 1.22-1.65) and 1.48 (95% CI 1.33-1.65), respectively.
Conclusion
Hypermagnesemia (Mg ≧2.3 mg/dL) was associated with increased in-hospital and 1-year mortality in critically ill AKI patients. Serum magnesium monitoring and proper magnesium level correction in critically ill patients with AKI should be considered. Further studies that evaluated the magnesium treatment effect are recommended.